Dr. Jarnagin on the Improvements in Surgery for Patients With mCRC

William R. Jarnagin, MD, FACS
Published: Monday, Feb 12, 2018



William R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the progression of surgery in treating patients with metastatic colorectal cancer (mCRC).

The surgical operations for patients with mCRC have become much safer, Jarnagin says. Surgeons tend to do fewer large resections and consequently remove less normal liver than they used to. Neoadjuvant approaches such as portal vein embolization of the liver is done more commonly to increase the safety of the operation. This procedure in particular increases the amount of functional liver left behind post-surgery.

A large number of segmental type resections are also done which allows surgeons to take patients into the operating room who have more advanced disease and an increasing number of tumors. In doing so, they can more effectively remove all of the disease.

The effectiveness of chemotherapy has also changed surgical approaches. More patients are receiving chemotherapy before surgery, and though patients have improved responses, subsequent regeneration of the future liver remnant may be compromised, he concludes.


William R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the progression of surgery in treating patients with metastatic colorectal cancer (mCRC).

The surgical operations for patients with mCRC have become much safer, Jarnagin says. Surgeons tend to do fewer large resections and consequently remove less normal liver than they used to. Neoadjuvant approaches such as portal vein embolization of the liver is done more commonly to increase the safety of the operation. This procedure in particular increases the amount of functional liver left behind post-surgery.

A large number of segmental type resections are also done which allows surgeons to take patients into the operating room who have more advanced disease and an increasing number of tumors. In doing so, they can more effectively remove all of the disease.

The effectiveness of chemotherapy has also changed surgical approaches. More patients are receiving chemotherapy before surgery, and though patients have improved responses, subsequent regeneration of the future liver remnant may be compromised, he concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x